RESUMEN
We investigated the prevalence of hepatitis C virus (HCV) co-infection in HIV-infected patients at a large Swedish outpatient clinic. We also evaluated the feasibility of treating this patient group with pegylated-interferon alpha-2a and ribavirin (RBV) and found that only a small fraction of the HCV/HIV co-infected patients met the criteria for HCV treatment when following international guidelines. Thus, 11 patients were treated, and HCV kinetics were measured during early treatment. The overall treatment response rate was surprisingly high (73%) and correlated to early virological response.
Asunto(s)
Instituciones de Atención Ambulatoria/estadística & datos numéricos , Infecciones por VIH/virología , Hepatitis C/tratamiento farmacológico , Hepatitis C/virología , Adulto , Antivirales/uso terapéutico , Estudios de Factibilidad , Femenino , Hepatitis C/genética , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Cinética , Masculino , Persona de Mediana Edad , Polietilenglicoles/uso terapéutico , Prevalencia , ARN Viral/sangre , Proteínas Recombinantes , Ribavirina/uso terapéutico , Suecia , Resultado del TratamientoRESUMEN
Chronic immune activation is a driver of human immunodeficiency virus type 1 (HIV-1) disease progression. Here, we describe that subjects with chronic hepatitis C virus (HCV)/HIV-1 coinfection display sharply elevated immune activation as determined by CD38 expression in T cells. This occurs, despite effective antiretroviral therapy, in both CD8 and CD4 T cells and is more pronounced than in the appropriate monoinfected control groups. Interestingly, the suppression of HCV by pegylated alpha interferon and ribavirin treatment reduces activation. High HCV loads and elevated levels of chronic immune activation may contribute to the high rates of viral disease progression observed in HCV/HIV-1-coinfected patients.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Antivirales/uso terapéutico , Infecciones por VIH , VIH-1/inmunología , Hepacivirus/inmunología , Hepatitis C Crónica , Ribavirina/uso terapéutico , Linfocitos T , ADP-Ribosil Ciclasa 1/inmunología , Adulto , Progresión de la Enfermedad , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/inmunología , Hepatitis C Crónica/virología , Humanos , Interferón-alfa/inmunología , Interferón-alfa/uso terapéutico , Activación de Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/virología , Linfocitos T/inmunología , Linfocitos T/virología , Carga Viral , Adulto JovenRESUMEN
The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma. Knowledge from population studies of the long-term risk of chronic HBV infection, as well as the recent introduction of pegylated interferon and additional nucleoside analogues has changed the therapeutic situation. Recently, a Swedish expert panel convened to update the national recommendations for treatment. The panel recommends treatment for patients with active HBV infection causing protracted liver inflammation or significant liver fibrosis, verified by liver histology. In general, pegylated interferon alpha-2a is recommended as first-line treatment, in particular for HBeAg-positive patients with HBV genotypes A or B. Among nucleoside analogues, entecavir is the first choice and adefovir or tenofovir can be used as alternatives. Lamivudine monotherapy is not recommended due to the high risk of resistance development. Combinations of nucleoside analogues such as tenofovir and lamivudine or emtricitabine are alternatives for patients with non-response or infection with resistant variants, or as first choice for patients with advanced liver disease. Nucleoside analogue treatment should be monitored to detect primary non-response and virological breakthrough. Special recommendations are given for HBV/HIV coinfected patients, immunosuppressed patients, children, and for treatment before and after liver transplantation. The present guideline is translated from Swedish, where it is published on the MPA and RAV websites (www.mpa.se and www.rav.nu.se) including 7 separate papers based on thorough literature search. The complete reference list can be received from the Medical Products Agency upon request.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis B Crónica/tratamiento farmacológico , Adenina/análogos & derivados , Adenina/uso terapéutico , Carcinoma Hepatocelular/prevención & control , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Quimioterapia Combinada , Emtricitabina , Guanina/análogos & derivados , Guanina/uso terapéutico , Infecciones por VIH/complicaciones , Hepatitis B Crónica/complicaciones , Humanos , Huésped Inmunocomprometido , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Lamivudine/uso terapéutico , Cirrosis Hepática/prevención & control , Trasplante de Hígado , Organofosfonatos/uso terapéutico , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes , Suecia , TenofovirRESUMEN
Co-infection with HCV and HIV-1 is a problem of increasing importance and the role of innate cellular immunity in this co-infection is incompletely understood. Here, we have observed sharply elevated numbers of CD56(-)CD16(+) perforin(low) NK cells in HCV/HIV-1 co-infected subjects on antiretroviral therapy. Interestingly, this expansion of unconventional CD56(-) NK cells rapidly reverted when HCV was suppressed by IFNalpha and ribavirin treatment, and was not seen in mono-infected control groups. In vitro experiments suggested that this effect of treatment was due to suppression of HCV viremia rather than a direct effect of IFNalpha on these cells. In contrast, the conventional CD56(+) NK cells were largely unchanged in subjects with high HCV loads, although they exhibited slightly decreased perforin expression. With delayed kinetics, the CD56(bright) immuno-regulatory NK cell subset temporarily increased to supranormal levels in response to HCV treatment. In contrast to the NK compartment, the CD1d-restricted NKT cells were severely reduced by the co-infection and not restored by treatment. Together, our data suggest that the high HCV loads in HCV/HIV-1 co-infection alter the NK cell compartment in a way not observed in HCV mono-infection.
Asunto(s)
Antivirales/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Hepatitis C Crónica/tratamiento farmacológico , Células Asesinas Naturales/efectos de los fármacos , Subgrupos Linfocitarios/efectos de los fármacos , Adulto , Anciano , Antígeno CD56/metabolismo , Femenino , Citometría de Flujo , Infecciones por VIH/complicaciones , Infecciones por VIH/inmunología , VIH-1 , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/inmunología , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Células Asesinas Naturales/inmunología , Subgrupos Linfocitarios/inmunología , Masculino , Persona de Mediana Edad , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes , Ribavirina/uso terapéutico , Viremia/tratamiento farmacológicoRESUMEN
OBJECTIVE: To evaluate compliance, serologic response and the cost-benefit of a low-dose intradermal hepatitis B vaccination programme, followed by intramuscular boosters in non-responders. MATERIAL AND METHODS: The study comprised a retrospective survey of 1521 health-care workers and 968 students. Response was defined as hepatitis B antibody titres > or =10 IU/L. Non-response included vaccinees with undetectable antibodies and a hypo-response if antibodies were detectable. RESULTS: Overall, 2145/2489 (86%) subjects completed the intradermal series, whereof 1840/2489 (74%) complied with the serological check-up. Response was achieved in 1517/1840 (82.5%), whereas 107/1840 (5.8%) had a hypo-response and 216/1840 (11.7%) had an undetectable response. In a logistic regression model, younger age (odds ratio 0.73 (95% CI: 0.65-0.82, p<0.001)) and female gender (odds ratio 2.16 (95% CI: 1.67-2.80; p<0.001)) were predictive of response. In hypo-responders and those with undetectable responses, 43/46 (94%) and 71/136 (52%), respectively, had a response after the first intramuscular booster. Hence, in compliant vaccinees an overall seroprotection rate of 94% was reached after a single intramuscular booster. A cost-benefit analysis indicated a cost reduction exceeding 50% compared to a standard intramuscular vaccine regimen. CONCLUSIONS: In the clinical setting, a low-dose intradermal hepatitis B vaccination programme, followed by intramuscular boosters to non-responders, is effective and cost saving.
Asunto(s)
Personal de Salud , Vacunas contra Hepatitis B/administración & dosificación , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Estudiantes de Medicina , Vacunación , Adulto , Análisis Costo-Beneficio , Recolección de Datos , Femenino , Anticuerpos contra la Hepatitis B/sangre , Vacunas contra Hepatitis B/economía , Humanos , Programas de Inmunización , Inmunización Secundaria , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/economía , Inyecciones Intradérmicas , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Vacunación/economía , Vacunas SintéticasRESUMEN
UNLABELLED: A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428 treatment-naïve HCV RNA-positive patients with genotype 2 or 3 were enrolled. Patients with RVR were randomized to 14 (group A) or 24 (group B) weeks of treatment. Patients were treated with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily. The noninferiority margin was set to be 10% between the two groups with a one-sided 2.5% significance level. RVR was obtained in 302 of 428 (71%), and 298 of these were randomized to group A (n = 148) or group B (n = 150). In the intention-to-treat analysis, SVR rates were 120 of 148 (81.1%) in group A and 136 of 150 (90.7%) in group B (difference, 9.6%; 95% confidence interval, 1.7-17.7). Among patients with an HCV RNA test 24 weeks after the end of treatment, 120 of 139 (86.3%) patients in group A achieved SVR compared with 136 of 146 (93.2%) in group B (difference, 6.9%; 95% confidence interval, -0.1 to +13.9). CONCLUSION: We cannot formally claim that 14 weeks of treatment is noninferior to 24 weeks of treatment. However, the SVR rate after 14 weeks of treatment is high, and although longer treatment may give slightly better SVR, we believe economical savings and fewer side effects make it rational to treat patients with genotype 2 or 3 and RVR for only 14 weeks.
Asunto(s)
Antivirales/administración & dosificación , Hepacivirus/efectos de los fármacos , Hepatitis C/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Ribavirina/administración & dosificación , Adolescente , Adulto , Anciano , Antivirales/efectos adversos , Antivirales/economía , Esquema de Medicación , Quimioterapia Combinada , Femenino , Genotipo , Hepacivirus/genética , Humanos , Interferón alfa-2 , Interferón-alfa/efectos adversos , Interferón-alfa/economía , Masculino , Persona de Mediana Edad , Polietilenglicoles , Proteínas Recombinantes , Ribavirina/efectos adversos , Ribavirina/economía , Carga Viral/estadística & datos numéricosRESUMEN
BACKGROUND/OBJECTIVE: Spontaneous HCV clearance in HCV/HIV-1 coinfected patients is likely to be very rare given the damage to the immune system caused by HIV-1 infection. The search for immune correlates of spontaneous clearance is important for the understanding of pathogenesis as well as for the development of possible new treatment strategies. STUDY DESIGN/RESULTS: A cohort of HCV/HIV-1 coinfected patients was followed. Plasma HCV viral load was measured and T cell immunity in peripheral blood samples was assessed using multi-color flow cytometry. One HCV/HIV-1 coinfected patient spontaneously became HCV-RNA negative after being positive for several years. This patient displayed a normalized CD4 counts on successful HAART, low level of T cell activation and a high level of T cell function as compared to HCV/HIV-1 coinfected control subjects. CONCLUSIONS: A beneficial immune status including a low level of chronic T cell activation and a high level of T cell function may be one factor that contributes to improved chances of clearance of chronic HCV infection in HIV-1 infected patients.
Asunto(s)
Infecciones por VIH , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica , Activación de Linfocitos/inmunología , Linfocitos T/inmunología , Recuento de Linfocito CD4 , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/inmunología , Infecciones por VIH/virología , VIH-1 , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/inmunología , Hepatitis C Crónica/virología , Humanos , Persona de Mediana EdadRESUMEN
The aim of the study was to assess the cost-effectiveness of peginterferon alfa-2b (pegIFN) compared to interferon alfa-2b (IFN), both in combination with ribavirin, as initial therapy for chronic hepatitis C in Sweden. A computer based Markov model describing the natural course of chronic hepatitis C was used to assess costs and quality-adjusted life-y (QALY) for the treatment strategies. Study population was a cohort of hepatitis C patients from the age of 43 y until death. Natural history and response data were obtained from the literature and from Swedish clinical experts. Costs were obtained from different health care providers in Sweden and based on Swedish clinical practice. In our base case analysis for genotype 1 patients, pegIFN plus ribavirin therapy generated 0.29 incremental QALYs and was cost saving (dominant strategy). Corresponding results for genotype 2/3 patients were 0.09 QALYs at an incremental cost of 941 euros (10,500 euros/QALY). A probabilistic sensitivity analysis was performed to study the stability of our results. From the results we conclude that for genotype 1 patients treatment with pegIFN and ribavirin increased quality-adjusted life expectancy and was cost-effective as initial therapy for hepatitis C. The cost-effectiveness for patients infected with genotype 2/3 was less obvious.
Asunto(s)
Antivirales/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Ribavirina/administración & dosificación , Adulto , Antivirales/economía , Análisis Costo-Beneficio , Quimioterapia Combinada , Costos de la Atención en Salud , Hepatitis C Crónica/economía , Humanos , Interferón alfa-2 , Interferón-alfa/economía , Cadenas de Markov , Método de Montecarlo , Polietilenglicoles , Calidad de Vida , Proteínas Recombinantes , Ribavirina/economía , SueciaRESUMEN
The aim of this study was to evaluate the association between hepatitis C virus (HCV) infection and non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), thyroid cancer (TC), chronic lymphatic leukemia (CLL), acute lymphatic leukemia (ALL), and Hodgkin's lymphoma (HL). A Swedish cohort of 27,150 HCV-infected persons notified during 1990-2000 was included in the study. The database was linked to other national registers to calculate the observation time, expressed as person-years, and to identify all incident malignancies in the cohort. The patients were stratified according to assumed time of previous HCV infection. The relative risk of malignancy was expressed as a standardized incidence ratio (SIR)-the observed number compared to the expected number. During 1990-2000 there were 50 NHL, 15 MM, 14 ALL, 8 TC, 6 CLL, and 4 HL diagnoses in the cohort. Altogether, 20 NHL, 7 MM, 5 TC, 4 CLL, 1 ALL, and 1 HL patient fulfilled the criteria to be included in the statistical analysis. The observation time was 122,272 person-years. The risk of NHL and MM was significantly increased in the stratum with more than 15 years of infection (SIR 1.89 [95% CI, 1.10-3.03] and 2.54 [95% CI, 1.11-5.69], respectively). The association was not significant in TC or CLL. In conclusion, we report the incidence of several malignancies in a nationwide cohort of HCV-infected persons. Although the delayed diagnosis of HCV probably has resulted in an underestimation of the risk, this study showed a significantly increased risk of NHL and MM.
Asunto(s)
Hepatitis C/complicaciones , Linfoma no Hodgkin/etiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/etiología , Masculino , Persona de Mediana Edad , Mieloma Múltiple/etiología , Neoplasias , Leucemia-Linfoma Linfoblástico de Células Precursoras/etiología , ARN Viral/análisis , Factores de Riesgo , Neoplasias de la Tiroides/etiologíaRESUMEN
In Stockholm, Sweden, the majority of pregnant women positive for hepatitis B surface antigen (HBsAg) are hepatitis Be antigen (HBeAg) negative. Newborns to HBeAg positive mothers receive vaccination and hepatitis B immunoglobulin (HBIg). Newborns to HBeAg negative mothers receive vaccine and HBIg only if the mothers have elevated ALT levels. The aim of this study was to retrospectively evaluate ALT levels as a surrogate marker for HBV DNA levels in HBeAg negative carrier mothers. Altogether 8947 pregnant women were screened for HBV markers from 1999 to 2001 at the Virology Department, Karolinska Hospital. Among mothers screened 192 tested positive for HBsAg (2.2%). 13 of these samples could not be retrieved. Of the remaining 179 sera, 8 (4%) tested positive for HBeAg and 171 (95.5%) were HBeAg negative. Among the HBeAg negative mothers, 9 had HBV DNA levels > 10(5) copies/ml, and of these 7 had normal ALT levels indicating low sensitivity of an elevated ALT level as a surrogate marker for high HBV DNA level. Furthermore, no correlation was found between ALT and HBV DNA levels. Hence, it is concluded that the use of ALT as a surrogate marker for high viral replication in HBeAg negative mothers could be questioned.
Asunto(s)
Alanina Transaminasa/sangre , Portador Sano/transmisión , Antígenos e de la Hepatitis B/análisis , Virus de la Hepatitis B/inmunología , Hepatitis B/transmisión , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Adulto , Secuencia de Bases , Biomarcadores/sangre , Estudios de Casos y Controles , Intervalos de Confianza , ADN Viral/análisis , Femenino , Hepatitis B/prevención & control , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Recién Nacido , Tamizaje Masivo , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa/métodos , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Resultado del Embarazo , Atención Prenatal , Probabilidad , Valores de Referencia , Estudios Retrospectivos , Sensibilidad y Especificidad , Pruebas Serológicas , Estadísticas no Paramétricas , SueciaRESUMEN
In 1999 a Swedish national expert panel published recommendations for the treatment of chronic hepatitis C (HCV) infection. Recently, pegylated interferon (peg-IFN) products have been introduced, and an increased knowledge concerning treatment of acute HCV and HCV-human immunodeficiency virus (HIV) coinfection has been gained. As a result of this, an update of the Swedish recommendations was developed following an expert meeting in October 2002. The panel now recommends the use of peg-IFN together with ribavirin as the standard treatment. Owing to the excellent response rates in HCV genotype 2 and 3 infections, these patients can be treated for 24 weeks without preceding liver biopsy. For patients with genotype 1 infection (with a slightly below 50% sustained response rate after 48 weeks treatment) and only mild histological disease, treatment can be postponed until future better treatment options become available. In patients who fail to achieve a 99% reduction (2 log drop) in viral titre after 12 weeks of treatment, discontinuation of therapy is recommended. Patients previously treated with IFN monotherapy and not having achieved a sustained virological response are recommended the same combination treatment as treatment-naive patients. IFN monotherapy is recommended in patients with acute hepatitis C. For children with chronic HCV infection, combination treatment is mainly recommended in clinical trials. For HCV-HIV coinfected patients, combination treatment is recommended and preferably given when blood CD4 counts are above 350/ml and before antiretroviral treatment (ART) is needed. Concurrent ART or prominent liver fibrosis requires frequent monitoring because of the increased risk for mitochondrial toxicity and liver failure.
Asunto(s)
Antivirales/uso terapéutico , Consenso , Hepatitis C Crónica/diagnóstico , Hepatitis C Crónica/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada , Femenino , Hepatitis C Crónica/epidemiología , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Pronóstico , Proteínas Recombinantes , Ribavirina/uso terapéutico , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Suecia/epidemiología , Resultado del TratamientoRESUMEN
Hepatitis C virus (HCV) RNA kinetics were studied at baseline weeks 4, 8 and 12 during interferon-alpha (IFN) monotherapy in 65 patients (mean age 39 y, range 19-66 y) with chronic HCV infection. IFN treatment was given either as initial induction (n = 34) or as standard dosing 3 times a week (n = 31). Patients with genotypes 2 and 3 had a significantly steeper decline in HCV RNA levels than patients with genotype 1 at weeks 4, 8 and 12 (p < 0.001 at all points measured). The decline in viral load was more pronounced in patients with induction therapy than with standard therapy at weeks 4, 8 and 12 (p < 0.02, 0.054 and 0.01, respectively). Patients with a sustained viral response had a 3-log decline in viral levels at week 4, with few exceptions. Two patients with non-response at week 12 (1 each with genotype 1 and non-1) responded after supplementation with ribavirin.